You are here

Point-of-care Nucleic Acid Assays

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-21-P-0003
Agency Tracking Number: A20B-T022-0100
Amount: $166,488.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: A20B-T022
Solicitation Number: 20.B
Solicitation Year: 2020
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-01-04
Award End Date (Contract End Date): 2021-08-03
Small Business Information
6820 Moquin Dr NW
Huntsville, AL 35806-2900
United States
DUNS: 185169620
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Ketan Bhatt
 (256) 726-4908
Business Contact
 Evan Richardson
Phone: (256) 361-0801
Research Institution
 HudsonAlpha Institute for Biotechnology
 Flo Behn
601 Genome Way
Huntsville, AL 35806-2908
United States

 (256) 327-0488
 Domestic Nonprofit Research Organization

Genomic and transcriptomic biomarkers have been identified that can be utilized for disease diagnosis, prognosis, and monitoring including cancers, cardiovascular health, depression, and sepsis. Genetic variations have also been identified that affect pharmacokinetics as well as pharmacologic effects of specific drugs. Current methods for detection and quantification of these nucleic acid biomarkers requires bulky equipment and trained laboratory personnel, with turnaround times ranging from few hours to several days. Even though, there has been development in portable PCR machines, these still need skilled staff, power and are not rugged for battlefield environments. There is a clear need to develop assays and instruments that can be utilized at the site to rapidly detect and quantify specific sets of genes including SNPs from a variety of different clinical samples. To address this need, we propose to develop novel point-of-care assay kits for precise, multiplexed detection of genetic variation. The assays kits will be low-cost, support no to low power operation, and provide rapid results. Phase I will establish proof-of-concept of the assays by demonstrating detection of selected gene variants of interest from spiked samples. Phase II will expand the multiplexing capabilities of the assay and build pre-production prototypes.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government